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a  b  s  t  r  a  c  t
Aim: Prognostic factors, rational management, and the ongoing investigations regarding
temporal bone squamous cell carcinoma (TBSCC) have been critically reviewed.
Background: TBSCC is an uncommon, aggressive malignancy. Although some progress has
been made in treating this aggressive tumor, the prognosis in advanced cases remains poor.
Materials and methods: A systematic search of the literature for articles published between
2009 and October 2014 was performed using the PubMed (http://www.pubmed.gov) elec-
tronic database.
Results: Given the particular anatomical site of TBSCC, its prognosis is significantly influ-
enced by any direct involvement of nearby structures. The extent of the primary tumor
is  generally considered one of the most important prognostic factors and it is frequently
related to prognosis even more strongly than N stage. For TBSCC, biomarker investigations
in  surgical specimens are only just beginning to appear in the oncological literature.
Conclusion: Given the particular features of TBSCC, the sub-specialty of otologic oncol-ogy  seems to be emerging as a defined area of practice involving multidisciplinary team
comprising oto-neurosurgeons, head and neck surgeons, plastic surgeons, oncologists,
radiotherapists, dedicated radiologists, and pathologists.
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.  Background
quamocellular carcinoma of external-middle ear is an
ncommon (less than 0.2% of head and neck cancers) and
ggressive malignancy. It accounts for the 60–80% of tumors
rising in the external auditory canal.1–3
The reason for this malignancy aggressiveness may be
ound in the disease biological behavior but also in the vari-
us potential routes of diffusion to the surrounding structures.
emporal bone does not protect from tumoral invasion and
icroscopic invasion seems to be frequent through the intra-
sseous vessels and Haversian canals. In available literature,
he association between the tumor and middle ear chronic
nflammatory disease has been reported,4,5 as well as genetic
redisposition.4 A role has been hypothesized for chlorinated
isinfectants in the etiopathogenesis of middle ear carcinoma
nd for human papillomavirus in cases of temporal bone
quamous cell carcinoma (TBSCC) associated with inverted
apilloma.6,7 TBSCC is usually diagnosed with delay1,4 since
linical signs (otorrhea, polyps or granulation tissue, hearing
oss, bleeding) and patients complaints (ear pain) are simi-
ar to other common inflammatory diseases of the ear. When
resent, facial nerve paralysis is a sign of advanced disease.
Perineural invasion and angio-lymphatic diffusion are local
eatures of tumor aggressiveness.4,8 The temporal bone may
e eroded by obvious extension or microscopic undetectable
ntra-osseus infiltration. Adjoining sites (jugular foramen,
ura mater, internal carotid artery, facial nerve, parotid,
ondyle) may be involved by local tumor growth. Diagnosis is
ostly clinico-radiological and necessarily confirmed by local
eep biopsies. Cervical lymphnodes metastases are relatively
ommon (10–20%).4,9,10 Temporal bone contrast-enhanced,
igh-resolution CT scan and MRI  are mandatory. Neck ultra-
onography and/or contrast-enhanced CT scan can effectively
nvestigate regional metastases. PET scan can be important to
ule out distant metastasis. Differential diagnosis involves1,4
kull base osteomyelitis, infectious complications of the skull
ase and other local neoplasms.
Curative treatment is an extensive radical surgery followed
y radiotherapy and chemotherapy in advanced stages or if
equired by postoperative pathological evidence (including
nvolved margins). The anatomical complexity of this area
nvolves technically difficult surgery and the need of extend-
ng the surgical field beyond macroscopically free margins in
rder to obtain oncologically safe margins.
Despite improvements in early diagnosis, surgical tech-
iques and adjuvant therapies, prognosis remains poor,
specially for advanced TBSCCs. It has been diffusely reported
hat several cases recurred even after radical surgical exci-
ion with pathologically free margins. Further investigations
xploring the biological behavior of the tumor seem nowadays
o be mandatory to predict prognosis and promote modern
reatments for TBSCC..  Aim
ritical review of the current status of knowledge, prognostic
actors, rational management and the ongoing investigationstherapy 2 1 ( 2 0 1 6 ) 386–390 387
regarding primary temporal bone squamous cell carcinoma
(TBSCC).
3.  Materials  and  methods
A systematic search of the literature for articles published
between 2009 and October 2014 was performed using the
PubMed (http://www.pubmed.gov) electronic database; only
articles in English were included. The searched terms used
were: “temporal bone cancer”, “temporal bone malignancy”,
“temporal bone carcinoma”, “ear malignancy”, “ear cancer”,
“ear carcinoma”. The “Related articles” option on the PubMed
homepage was also considered. Some papers were found in
more  than one search. The texts of the publications identi-
fied were screened for original data and reference lists were
checked for other relevant studies.
Studies considered acceptable for inclusion were those
addressing TBSCC prognostic factors. All investigations dis-
cussing malignancies other than squamous cell carcinoma,
case reports, very limited series, and clinical reviews were
excluded. Other recent series referring to carcinoma of the
parotid skin, retroauricular, preauricular area involving the
external-middle ear were also excluded.
4.  Results
4.1.  Conventional  clinico-pathological  variables  and
prognosis
Among the considered series, the significant prognostic
factors in terms of disease-free survival (DFS) and disease-
specific survival (DSS) were critically analyzed.
The pathological status of surgical margins was diffusely
reported as the main factor influencing the outcome and
the recurrence rate,10–16 although how reliable “free margins”
could be in the bone is still a matter of discussion.10
There is quite a general agreement on the significant role of
T stage according to the Pittsburgh staging system10,12,13,15,16
as a factor determining prognosis, since the latter was good
in T1–T2 and poor in T3–T4. The different outcome of the
group of patients with anterior vs. non-anterior extension
of T4 tumors was recently investigated17 showing a signifi-
cantly better prognosis in the anterior T4. The proposal of a
modified classification system for tumor local extension has
been reported in a recent paper by Mazzoni et al.17 (Table 1).
Extensive erosion of the bone was also a negative progno-
stic factor.11,13,16,17 The pathological grading of the tumor was
reported as a factor related to worse prognosis only in a limited
number of series.10,18 In part, facial nerve involvement contin-
ues to be controversial with a significant negative prognostic
role found by most11,12,15,16,19–22 but not all groups.23 Dura
mater infiltration evidence (both radiological and/or patho-
logical) was reported in most of the series10,11,21,22 as the
strongest negative prognostic factor affecting survival.Different conclusions have been reported about the pro-
gnostic value of neck lymph-nodes clinical status (cN).
Clinically positive neck has been significantly related with
poor prognosis by some groups10,11,18,21,22 but not by others.23,8
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Table 1 – SCC of ear temporal bone. A new classification
system.
Stage Site and subsites
T1 Tumor in skin with no bone involvement
T2 Tumor in skin with bone/cartilage involvement, but
not full thickness
T3a Tumor extending <5 mm from cartilage to
periauricular soft tissues, or
Tumor strictly limited to the anterior bone wall and
growing <5 mm into the parotid space
T3b Same as for T3a, but extending >5 mm
T4a Tumor growing into the mastoid, without 7th nerve
palsy
T4b Tumor growing into the mastoid with facial palsy, or
into the infratemporal space, or the medial wall of
the tympanum, or labyrinth, or petrous bone
(jugular foramen, internal carotid canal, petrous
This makes it difficult to compare results and complicatesapex)
Modified by Mazzoni et al.17
4.2.  Biomarkers  and  temporal  bone  carcinoma
prognosis
Despite the increasing interest and the recent investigations
about rational therapeutic approaches and prognosis of TBSCC
previously critically analyzed, rare attempts have tried to go
beyond clinical studies focusing on the biologic mechanisms
behind these malignancies.6,10 Molecular markers, detectable
by means of reliable assays, have to precisely characterize
tumor’s biological and clinical behavior. Molecular markers
are demonstrable cellular alterations which may be genetic,
epigenetic or phenotypic, but are in any case the expression of
one or more  neoplastic steps.24 One of the goals of biomarker
analysis in oncology is to establish a patient’s prognosis.
Another goal of such analyses is to ascertain the radio- and
chemosensitivity profiles of individual temporal malignan-
cies, so that a truly personalized therapy can be administered.
The third goal is to find targets for therapeutic agents as Cetux-
imab (an IgG1 chimeric human/murine monoclonal antibody
that binds to EGFR with a high affinity) that is, at the moment,
the only molecular targeting agent used in head and neck
carcinoma.25
Considering that carcinoma cells seem to activate a dor-
mant epithelial–mesenchymal transition program to promote
cell migration, invasion and metastasis, Sugimoto et al.26 ret-
rospectively examined the role of epithelial–mesenchymal
transition in 16 cases of TBSCC. Sugimoto et al.26 reported
that statistical analysis failed in confirming significant dif-
ferences in disease-specific survival between patients with
and without epithelial-mesenchymal transition. Recognizing
the importance of neoangiogenesis in the growth of solid
malignancies, Marioni et al.27 investigated in a series of 20
consecutive TBSCCs the role of the expression of endoglin
(CD105), a proliferation-associated protein expressed in angio-
genic endothelial cells.28 CD105 stained intra-tumor vessels
intensively, while there was little or no reaction to CD105 in
the vessels of normal healthy tissues adjacent to TBSCC. The
recurrence rate was significantly higher and the disease-free
survival shorter in TBSCCs with CD105 expression of 9.44%
or higher than in TBSCCs where it was less than 9.44%. Theiotherapy 2 1 ( 2 0 1 6 ) 386–390
crude carcinoma recurrence risk ratio was 5.9 times higher
for patients whose CD105 expression was ≥9.44%. The pro-
tein MASPIN reveals a unique tumor-suppressing activity and
has been found to inhibit tumor growth and metastasis in
numerous models and cancer types.29 In 2013, Marioni et al.30
studied the role of the tumor suppressor protein MASPIN in
TBSCC, finding subcellular cytoplasmic MASPIN expression
significantly higher in patients who had experienced no recur-
rence of their carcinoma. In the same year, Marioni et al.31
investigated the prognostic role of phosphorylated (activated)
signal transducer and activator of transcription 3 (STAT3) in
TBSCC. pSTAT3 over-expression occurs in a variety of malig-
nancies, suggesting that STAT3 may be not only prognostically
important but also a potential target for therapy, and several
strategies are being developed to target the STAT3 signaling
pathway. Unfortunately, Marioni et al.31 found no significant
correlations between phosphorylated STAT3 expression in
tumor cells and DFS or DSS in TBSCC patients.
5.  Conclusions
The homogeneity of a given series is very important when
considering the prognostic factors for carcinoma of the exter-
nal ear-temporal bone. This was at the base of our critical
revision of literature.
This tumor carries a worse prognosis than other histotypes
in the same sites and subsites.
Prognosis is influenced by the pathological status of the
margins, stage of the disease, degree of differentiation, facial
nerve and dura mater involvement.
The radicality achieved with extensive surgery is the
most important independent factor influencing prognosis10–16
though it is not clear how surgical margins can be really con-
sidered “free” in the bone.10 The en-bloc resections with lateral
or subtotal temporal bone resections (LTBR and STBR), though
more likely to ensure gross radicality, encounter the prob-
lem of microscopic diffusion in the bone and may explain the
relatively high recurrence rate also after surgery with patho-
logically free margins. The mainstay of treatment is extensive
radical surgery to ensure negative margins,10,30 but this is par-
ticularly difficult to achieve when the bone is infiltrated. It is
definitely controversial to what extent LTBR or STBR should be
enlarged beyond the “free” margins.
There is general agreement10,12,13,15,16 about the poor
prognosis of locally advanced stages, although tumors with
anterior extension into soft tissues showed better prognosis
than other (medial, posterior, inferior) extensions.17 A new
staging system was thus proposed17 (Table 1) to differentiate
these different sites of tumoral infiltration and give them a
prognostic value.
At now, there is no widely accepted system for classifying
squamous cell carcinoma of the external ear and temporal
bone. Different classifications have been proposed,6 but none
have been accepted by the International Union Against Cancer
(UICC) or the American Joint Committee on Cancer (AJCC).32efforts to identify prognostic factors.
Preoperative involvement of the facial nerve is consid-
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niversally recognized.23 Facial nerve sacrifice was also
elated to poor prognosis,10 both in the condition of clinical
reoperative involvement and in the necessity to sacrifice it for
ncological reasons in the surgical approach. Dural infiltration
as the strongest reported negative factor affecting survival.
he resection of infiltrated dura, although technically feasi-
le, did not prevent recurrences and strongly affected poor
urvival. The opportunity of a curative surgery when dura is
nfiltrated is questionable and the option of palliation may be
onsidered as a reasonable alternative.
Our critical analysis of prognostic factors showed how
ggressive the tumor is and how survival is poor in advanced
tages. Radical surgery is the mainstay of treatment and
he status of the margin is one of the most important
spect determining prognosis. Adjuvant radiotherapy has
howed improvement in the loco-regional control of advanced
isease6,13 and it is mandatory also after radical surgery.
But despite the oncological principles being respected in
he management of this tumor and the role of adjuvant radio-
herapy, the poor prognosis of advanced stages remains a fact.
Molecular changes occur in malignancies some time before
ny morphological changes become visible, and the former are
esponsible for the disease’s biological behavior, prognosis and
esponse to primary therapy. It is crucial to search for biomark-
rs that might reflect the biological characteristics of TBSCC
nd help clinicians to predict the outcome of treatment.6 For
BSCC such investigations are only just beginning to appear
n the oncological literature. Biomarkers could be extremely
mportant to the development of novel, integrated therapeutic
trategies (including targeted approaches) capable of improv-
ng the DFS and DSS for patients with advanced TBSCC.
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